Redeye was quite surprised by the strong growth in Q4, almost 10% organically.
Yesterday, 2.72m already existing MHP Hotel shares were successfully placed (oversubscribed), equiva...
Redeye provides an update on AlzeCure Pharma following the out-licensing of Alzstatin ACD680 to Eli ...
We trim 2026E-28E adjusted EBITA by 2% ahead of the Q2 report due on 15 July, mainly due to persiste...
Bittium today published new solutions to improve its position.
* Merchant-first platform in a fragmented Nordic market * Loan book growth transforms volumes into r...
Redeye comments on 4C Group’s fully secured rights issue of approximately SEK54m, with a potential o...
AlzeCure has out-licensed the global rights for Alzstatin ACD680 to Eli Lilly in a deal potentially ...
We expect healthy demand to have continued into Q2/26, which, together with a more balanced cost bas...
Kan bolaget skala upp genom ett skifte i intäktsmixen, eller skapar förvärvsstrategin problem med in...
This morning, Moberg Pharma and Karo Healthcare announced an expansion of their licensing agreement ...
A more supportive jackpot environment should drive a visible acceleration in ZEAL's Q2 billings.
Redeye is positive on the news flow over the past week, highlighting that Senzime continues to stren...
Redeye comments on the terms in Annexin’s rights issue and recent newsflow, which includes updates f...
Markets have rewarded our recent conviction. In this update, we trim one position back to 5%, taking...
Redsense Medical levererade en omsättningstillväxt om 34 procent till 6,4 MSEK och ett positivt röre...
The FDA has accepted Xbrane's BLA resubmission for Lucamzi and set a BsUFA action date of 29 October...
• Considering the alternatives in wound treatment • Discussions about investigator-initiated studies...
Sprint Bioscience intar en speciell roll inom svensk läkemedelsutveckling.
DO & CO looks set to report solid Q4 results on June 11.